KaliVir and Roche Enters into a Global Licensing Agreement to Discover, Develop and Commercialize Novel Oncolytic Vaccinia Viruses
Shots:
- KaliVir will receive an upfront payment & may be eligible to receive research, development & commercial milestone payments along with tiered royalties on commercial sales of the products developed by both the companies
- Roche will receive an exclusive license to discover, develop & commercialize the oncolytic vaccinia virus products generated by KaliVir through its VET platform. Both the companies will work towards advancing KaliVir’s VET platform
- KaliVir’s VET platform in combination with genetic modifications enhances the vaccinia viral backbone & also maximizes tumor killing, systemic delivery, & spread
Ref: PR Newswire | Image: KaliVir
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
